PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29226313-0	2018	Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.	alectinib	70-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30	
31068367-0	2019	Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance.	alectinib	16-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102	
29226313-6	2018	This work supports that alectinib can be prescribed without dose adjustment for CYP-mediated DDI liabilities.	alectinib	24-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83	
29226313-2	2018	Alectinib and its major active metabolite M4 exhibited drug-drug interaction (DDI) potential through cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C8 in vitro.	alectinib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116	
29226313-2	2018	Alectinib and its major active metabolite M4 exhibited drug-drug interaction (DDI) potential through cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C8 in vitro.	alectinib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121	
27841077-3	2017	The purpose of this study was to evaluate in vitro the potential to inhibit and induce cytochrome P450 (CYP) isoforms for alectinib and its major metabolite M4.	alectinib	122-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102	
27841077-3	2017	The purpose of this study was to evaluate in vitro the potential to inhibit and induce cytochrome P450 (CYP) isoforms for alectinib and its major metabolite M4.	alectinib	122-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-107	
27841077-8	2017	Out of the seven CYP isoforms in HLM, alectinib and M4 showed time-dependent inhibition (TDI) of only CYP3A4, which suggests low TDI potential due to low inactivation efficiency.	alectinib	38-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20	
27841077-12	2017	In summary, the risk of alectinib causing drug-drug interactions with coadministered drugs is expected to be low due to the weak potential of CYP inhibition and induction estimated in the preclinical studies.	alectinib	24-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-145